Melanoma cell lines show high-level expression of markers targeted by immunotherapy
November 2017
Lewis Katz School of Medicine at Temple University, Philadelphia, USA
Cytotoxic T Lymphocyte Antigen 4 (CTLA4) is a glycoprotein expressed on the surface of activated T cells; it acts as a potent inhibitor of the cytotoxic T lymphocyte activation and thus a key negative regulator of anti-tumor activity. Thus, Anti-CTLA4 immunotherapy is highly effective at reactivating T cell responses against cancer, in particular melanoma. In the present study, the researchers show that CTLA-4 is also highly expressed by most human melanoma cell lines. Also, the researchers checked by RNA sequencing the upregulation of genes downstream of molecular cascades triggered by CTLA-4. Taken together, the results raise the possibility that CTLA-4 targeting on melanoma cells may contribute to the clinical immunobiology of anti-CTLA-4 responses.
Interferon-gamma signaling in melanocytes and melanoma cells regulates expression of CTLA-4
M. Raza Zaidi
Added on: 09-13-2021
[1] https://cancerres.aacrjournals.org/content/78/2/436[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
